An observational study in Valve Disease, Heart, sponsored by National Heart Centre Singapore. Recruiting at 8 sites in 6 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by National Heart Centre Singapore · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A retrospective and prospective, observational, multicenter cohort study of consecutive patients undergoing transcatheter mitral/tricuspid ViV or ViR procedure with balloon expandable valve across participating sites in Asia-Pacific.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
This study's planned enrollment of 150 is below the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Browse Heart Valve Diseases studies →National Heart Centre Singapore is the lead sponsor of 63 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients undergoing transcatheter mitral/tricuspid ViV or ViR procedure with balloon expandable valve across participating sites in Asia-Pacific from 1 Jan 2023 to 31 Dec 2035.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have undergone or will undergo a transcatheter mitral valve-in-valve procedure.
Patients who have undergone or will undergo a transcatheter mitral valve-in-ring procedure.
Patients who have undergone or will undergo a transcatheter tricuspid valve-in-valve procedure.
Patients who have undergone or will undergo a transcatheter tricuspid valve-in-ring procedure.
All-cause mortality
Time frame: From date of procedure to 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2035, 129 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 129 months is above that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Heart Centre Singapore